{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:29:24Z","timestamp":1790231364280,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001922","name":"Efficacy and Mechanism Evaluation Programme","doi-asserted-by":"publisher","award":["14\/200\/18"],"award-info":[{"award-number":["14\/200\/18"]}],"id":[{"id":"10.13039\/501100001922","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Osteogenesis imperfecta (OI) is a rare disorder causing multiple fractures throughout life. No treatment has been shown to reduce the risk of fractures in OI. Here, we present the baseline characteristics of participants in the\n                      <jats:underline>T<\/jats:underline>\n                      reatment of\n                      <jats:underline>O<\/jats:underline>\n                      steogenesis Imperfecta with\n                      <jats:underline>P<\/jats:underline>\n                      arathyroid Hormone\n                      <jats:underline>a<\/jats:underline>\n                      nd\n                      <jats:underline>Z<\/jats:underline>\n                      oledronic Acid (TOPaZ) trial. The aim of the trial is to determine whether teriparatide and zoledronic acid are superior to standard care in reducing the risk of clinical fractures.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We summarised data on the baseline characteristics of TOPaZ participants, including demographics, genetic diagnosis, clinical features, bone density measurements, previous treatments, and fracture history.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We recruited 350 adults with a clinical diagnosis of OI in 27 European referral centres between June 2017 and October 2022. Overall, 266 (76.2%) had type I OI, 55 (15.8%) had type IV, and 19 (5.4%) had type III. The type was unknown in 9 (2.6%). Blue sclera were noted in 80.8%, and 35.8% had dentinogenesis imperfecta. Bisphosphonates had been administered to 28.1% in the 2 years prior to enrolment. Pathogenic variants in\n                      <jats:italic>COL1A1<\/jats:italic>\n                      or\n                      <jats:italic>COL1A2<\/jats:italic>\n                      were found in 87.6%. Fractures occurring in the 2 years prior to enrolment were not associated with bone density.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The TOPaZ population represents a unique cohort with which to study the genetic epidemiology and outcome of OI in relation to bone density and biochemical markers of bone turnover. When the trial reports, it will also provide new insights into the effect of an anabolic therapy, followed by antiresorptive treatment in the management of OI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00223-025-01440-3","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T18:35:19Z","timestamp":1762626919000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Baseline Characteristics of the TOPaZ Study: Randomised Trial of Teriparatide and Zoledronic Acid Compared with Standard Care in Adults with Osteogenesis Imperfecta"],"prefix":"10.1007","volume":"116","author":[{"given":"Jannie Dahl","family":"Hald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Weir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona","family":"Keerie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Dewar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morag","family":"MacLean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynsey","family":"Milne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Keen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Poole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bente","family":"Langdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazim","family":"Ghouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary J","family":"Hollick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Aspray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel K.","family":"Crowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Cohen-Solal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaki","family":"Hassan-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Tuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Marelise W.","family":"Eekhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Feenstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geeta","family":"Hampson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Turton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashanth","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mashood","family":"Siddiqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Munro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Paskins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Narayanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Malcolm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Kassim","family":"Javaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Osborne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C. Y.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly A.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Duckworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navnit","family":"Makaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Stenhouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2804-7586","authenticated-orcid":false,"given":"Stuart H.","family":"Ralston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,8]]},"reference":[{"key":"1440_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-024-01236-x","author":"JD Hald","year":"2024","unstructured":"Hald JD, Langdahl B, Folkestad L, Wekre LL, Johnson R, Nagamani SCS, Raggio C, Ralston SH, Semler O, Tosi L, Orwoll E (2024) Osteogenesis imperfecta: skeletal and non-skeletal challenges in adulthood. Calcif Tissue Int. https:\/\/doi.org\/10.1007\/s00223-024-01236-x","journal-title":"Calcif Tissue Int"},{"key":"1440_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/jbmr.2920","volume":"32","author":"L Folkestad","year":"2017","unstructured":"Folkestad L, Hald JD, Ersboll AK, Gram J, Hermann AP, Langdahl B, Abrahamsen B, Brixen K (2017) Fracture rates and fracture sites in patients with Osteogenesis Imperfecta: a nationwide register-based cohort study. J Bone Miner Res 32:125\u2013134. https:\/\/doi.org\/10.1002\/jbmr.2920","journal-title":"J Bone Miner Res"},{"key":"1440_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094963","author":"VL Gremminger","year":"2021","unstructured":"Gremminger VL, Phillips CL (2021) Impact of intrinsic muscle weakness on muscle-bone crosstalk in Osteogenesis imperfecta. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22094963","journal-title":"Int J Mol Sci"},{"key":"1440_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-024-01266-5","author":"M Jovanovic","year":"2024","unstructured":"Jovanovic M, Marini JC (2024) Update on the genetics of Osteogenesis Imperfecta. Calcif Tissue Int. https:\/\/doi.org\/10.1007\/s00223-024-01266-5","journal-title":"Calcif Tissue Int"},{"key":"1440_CR5","unstructured":"Folkestad L (2018) Mortality and morbidity in patients with osteogenesis imperfecta in Denmark. Dan Med J 65, https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29619932"},{"key":"1440_CR6","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1007\/s00198-018-4663-x","volume":"29","author":"JD Hald","year":"2018","unstructured":"Hald JD, Folkestad L, Swan CZ, Wanscher J, Schmidt M, Gjorup H, Haubek D, Leonhard CH, Larsen DA, Hjortdal JO, Harslof T, Duno M, Lund AM, Jensen JB, Brixen K, Langdahl B (2018) Osteogenesis imperfecta and the teeth, eyes, and ears-a study of non-skeletal phenotypes in adults. Osteoporos Int 29:2781\u20132789. https:\/\/doi.org\/10.1007\/s00198-018-4663-x","journal-title":"Osteoporos Int"},{"key":"1440_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.116222","volume":"154","author":"JD Andersen","year":"2022","unstructured":"Andersen JD, Folkestad L, Hald JD, Harslof T, Langdahl BL, Abrahamsen B (2022) Osteoarthritis in osteogenesis imperfecta: a nationwide register-based cohort study. Bone 154:116222. https:\/\/doi.org\/10.1016\/j.bone.2021.116222","journal-title":"Bone"},{"key":"1440_CR8","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13023-024-03126-9","volume":"19","author":"I Westerheim","year":"2024","unstructured":"Westerheim I, Hart T, van Welzenis T, Wekre LL, Semler O, Raggio C, Bober MB, Rapoport M, Prince S, Rauch F (2024) The IMPACT survey: a mixed methods study to understand the experience of children, adolescents and adults with osteogenesis imperfecta and their caregivers. Orphanet J Rare Dis 19:128. https:\/\/doi.org\/10.1186\/s13023-024-03126-9","journal-title":"Orphanet J Rare Dis"},{"key":"1440_CR9","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/jbmr.2410","volume":"30","author":"JD Hald","year":"2015","unstructured":"Hald JD, Evangelou E, Langdahl BL, Ralston SH (2015) Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials. J Bone Miner Res 30:929\u2013933. https:\/\/doi.org\/10.1002\/jbmr.2410","journal-title":"J Bone Miner Res"},{"key":"1440_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005088.pub4","author":"K Dwan","year":"2016","unstructured":"Dwan K, Phillipi CA, Steiner RD, Basel D (2016) Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD005088.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"1440_CR11","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1172\/JCI71101","volume":"124","author":"ES Orwoll","year":"2014","unstructured":"Orwoll ES, Shapiro J, Veith S, Wang Y, Lapidus J, Vanek C, Reeder JL, Keaveny TM, Lee DC, Mullins MA, Nagamani SC, Lee B (2014) Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. J Clin Invest 124:491\u2013498","journal-title":"J Clin Invest"},{"key":"1440_CR12","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/jbmr\/zjae112","volume":"39","author":"FH Glorieux","year":"2024","unstructured":"Glorieux FH, Langdahl B, Chapurlat R, De Beur SJ, Sutton VR, Poole KES, Dahir KM, Orwoll ES, Willie BM, Mikolajewicz N, Zimmermann E, Hosseinitabatabaei S, Ominsky MS, Saville C, Clancy J, MacKinnon A, Mistry A, Javaid MK (2024) Setrusumab for the treatment of osteogenesis imperfecta: 12-month results from the phase 2b asteroid study. J Bone Miner Res 39:1215\u20131228. https:\/\/doi.org\/10.1093\/jbmr\/zjae112","journal-title":"J Bone Miner Res"},{"key":"1440_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-078164","volume":"13","author":"JD Hald","year":"2023","unstructured":"Hald JD, Keerie C, Weir CJ, Javaid MK, Lam W, Osborne P, Walsh J, Langdahl BL, Ralston SH (2023) Protocol of a randomised trial of teriparatide followed by zoledronic acid to reduce fracture risk in adults with osteogenesis imperfecta. BMJ Open 13:e078164. https:\/\/doi.org\/10.1136\/bmjopen-2023-078164","journal-title":"BMJ Open"},{"key":"1440_CR14","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL, Committee ALQA (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17:405\u2013424. https:\/\/doi.org\/10.1038\/gim.2015.30","journal-title":"Genet Med"},{"key":"1440_CR15","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137\u20131148. https:\/\/doi.org\/10.1002\/jbmr.5650080915","journal-title":"J Bone Miner Res"},{"key":"1440_CR16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1385\/jcd:6:2:173","volume":"6","author":"D Gatti","year":"2003","unstructured":"Gatti D, Colapietro F, Fracassi E, Sartori E, Antoniazzi F, Braga V, Rossini M, Adami S (2003) The volumetric bone density and cortical thickness in adult patients affected by osteogenesis imperfecta. J Clin Densitom 6:173\u2013177. https:\/\/doi.org\/10.1385\/jcd:6:2:173","journal-title":"J Clin Densitom"},{"key":"1440_CR17","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1136\/pgmj.70.820.104","volume":"70","author":"CR Paterson","year":"1994","unstructured":"Paterson CR, Mole PA (1994) Bone density in osteogenesis imperfecta may well be normal. Postgrad Med J 70:104\u2013107","journal-title":"Postgrad Med J"},{"key":"1440_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11657-011-0054-z","volume":"6","author":"LL Wekre","year":"2011","unstructured":"Wekre LL, Eriksen EF, Falch JA (2011) Bone mass, bone markers and prevalence of fractures in adults with osteogenesis imperfecta. Arch Osteoporos 6:31\u201338. https:\/\/doi.org\/10.1007\/s11657-011-0054-z","journal-title":"Arch Osteoporos"},{"key":"1440_CR19","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/ejhg.2015.81","volume":"23","author":"K Lindahl","year":"2015","unstructured":"Lindahl K, Astrom E, Rubin CJ, Grigelioniene G, Malmgren B, Ljunggren O, Kindmark A (2015) Genetic epidemiology, prevalence, and genotype-phenotype correlations in the Swedish population with osteogenesis imperfecta. Eur J Hum Genet 23:1042\u20131050. https:\/\/doi.org\/10.1038\/ejhg.2015.81","journal-title":"Eur J Hum Genet"},{"key":"1440_CR20","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/ejhg.2015.129","volume":"23","author":"K Lindahl","year":"2015","unstructured":"Lindahl K, Astrom E, Rubin CJ, Grigelioniene G, Malmgren B, Ljunggren O, Kindmark A (2015) Genetic epidemiology, prevalence, and genotype-phenotype correlations in the Swedish population with osteogenesis imperfecta. Eur J Hum Genet 23:1112. https:\/\/doi.org\/10.1038\/ejhg.2015.129","journal-title":"Eur J Hum Genet"},{"key":"1440_CR21","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1007\/s00198-016-3653-0","volume":"27","author":"JD Hald","year":"2016","unstructured":"Hald JD, Folkestad L, Harslof T, Lund AM, Duno M, Jensen JB, Neghabat S, Brixen K, Langdahl B (2016) Skeletal phenotypes in adult patients with osteogenesis imperfecta-correlations with COL1A1\/COL1A2 genotype and collagen structure. Osteoporos Int 27:3331\u20133341. https:\/\/doi.org\/10.1007\/s00198-016-3653-0","journal-title":"Osteoporos Int"},{"key":"1440_CR22","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1007\/s00198-019-05076-6","volume":"30","author":"Y Ohata","year":"2019","unstructured":"Ohata Y, Takeyari S, Nakano Y, Kitaoka T, Nakayama H, Bizaoui V, Yamamoto K, Miyata K, Yamamoto K, Fujiwara M, Kubota T, Michigami T, Yamamoto K, Yamamoto T, Namba N, Ebina K, Yoshikawa H, Ozono K (2019) Comprehensive genetic analyses using targeted next-generation sequencing and genotype-phenotype correlations in 53 Japanese patients with osteogenesis imperfecta. Osteoporos Int 30:2333\u20132342. https:\/\/doi.org\/10.1007\/s00198-019-05076-6","journal-title":"Osteoporos Int"},{"key":"1440_CR23","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1359\/jbmr.2003.18.1.126","volume":"18","author":"S Adami","year":"2003","unstructured":"Adami S, Gatti D, Colapietro F, Fracassi E, Braga V, Rossini M, Tato L (2003) Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res 18:126\u2013130","journal-title":"J Bone Miner Res"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-025-01440-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-025-01440-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-025-01440-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T13:21:29Z","timestamp":1766755289000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-025-01440-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,8]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1440"],"URL":"https:\/\/doi.org\/10.1007\/s00223-025-01440-3","relation":{},"ISSN":["1432-0827"],"issn-type":[{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,8]]},"assertion":[{"value":"5 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Stuart H Ralston reports funding to his institution from Kyowa Kirin, UCB, and the Royal Osteoporosis Society outside the submitted work; Richard Keen reports personal funding from Mereo Biopharma; he is Chairperson of the Scientific Advisory Committee of the Brittle Bone Society; a member of the NHS England Clinical Reference Group for Specialized Rheumatology and Clinical Lead for the London Rare Disease Collaborative Network in Adult Rare Bone Conditions. Jennifer Walsh reports that she is a co-investigator on a clinical trial of losartan in OI (MOI-A study). Bente Langdahl reports personal consultancy fees from Mereo Biopharma, UCB, Gedeon-Richter, EnteraBio, Samsung-Bioepis, and Angitia and honoraria from Amgen, outside the submitted work, and that she is a board member of the Danish Osteoporosis Society. Rachel K Crowley reports grants from the Health Research Board Ireland for the Rare Disease Clinical Trial Network and Rare Disease Research Catalyst Consortium and funding to her institution from Kyowa Kirin; Zaki Hassan-Smith reports consulting fees and support for attending meetings from Ascendis Pharma, Alexion, and UCB Pharma; honoraria from Ascendis Pharma and Kyowa-Kirin outside the submitted work; and that he is a member of the Royal Osteoporosis Society Clinical Research Committee and Society for Endocrinology Corporate Liaison Committee. Mashood Siddiqi reports honoraria from Flynn Pharma, Thornton & Ross Pharma, and Eli Lilly; Matthew Roy reports consultancy fees from Mereo Biopharma and Kyowa Kirin. Zoe Paskins reports funding to her institution from NIHR, Versus Arthritis, the Royal Osteoporosis Society, and UCB Pharma outside the submitted work; consulting fees from UCB Pharma and the Royal College of General Practitioners outside the submitted work; and that she was former Chair of the Versus Arthritis Musculoskeletal Research Advisory Group and is current Chair of the Haywood Foundation Charity. Kassim Javaid reports grant funding to his institution from Kyowa Kirin, consulting fees from Kyowa Kirin, Nanox-AI, UCB, and Naitive Technologies; honoraria from Kyowa Kirin, UCB, Amgen, and Theramex; support for attending meetings from Kyowa Kirin and UCB; participation in an advisory board for Regeneron, and that he is an unpaid treasurer for the UK Fragility Fracture Network. Andrew Duckworth reports funding to his institution from the NIHR, Orthopaedic Trauma Association, and SORT-IT outside the submitted work; personal funding from Elsevier and Taylor and Francis outside the submitted work; personal honoraria from Angoves Healthcare, Swemac, and Smith and Nephew outside the submitted work. The remaining authors have no conflict of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This research was conducted with the approval of the West of Scotland Research Ethics Committee 3 (18\/WS\/0236).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"The study did not involve experimental animals. All participants gave written informed consent prior to taking part. For the purpose of open access, the author has applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising from this submission.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}}],"article-number":"136"}}